R
Ray Therapeutics
Developing optogenetic gene therapies to restore vision in patients with blinding diseases
About Ray Therapeutics
Ray Therapeutics is a cutting-edge biotech startup that operates in the healthcare sector. The company is focused on restoring vision through the use of optogenetics, a biological technique that involves the use of light to control cells in living tissue. This technique is typically used in neuroscience to control neurons, but Ray Therapeutics is applying it to the field of ophthalmology.
Read full description
The company's primary clients are individuals suffering from vision loss or impairment. By harnessing the power of optogenetics, Ray Therapeutics aims to offer a revolutionary solution to restore vision, which could potentially transform the lives of millions of people worldwide.
Ray Therapeutics operates in the biotechnology market, a sector that is expected to grow significantly in the coming years due to advancements in technology and increased demand for innovative healthcare solutions. The company's business model is likely based on the development and commercialization of its optogenetics technology. Once the technology is fully developed and approved for use, the company could generate revenue through the sale of its therapeutic solutions to healthcare providers or directly to patients.
In summary, Ray Therapeutics is a promising startup that is leveraging advanced biotechnology to potentially revolutionize vision restoration. The company operates in a growing market and serves a significant patient population, positioning it well for future success.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Berkeley, United States
- Employees
- 40
- Open positions
- 16
- Dealroom signal
- 88.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Ophthalmology, Genetics and genomics, Eye Diseases, Gene Therapy, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2026 | $125M | $500M | MRL Ventures · Marshall Wace · Franklin Templeton · Janus Henderson Investors | ↗ |
| GRANTOther financing | Nov 2023 | $4M | — | California Institute for Regenerative Medicine | ↗ |
Growth signals
Latest recorded traffic for Ray Therapeutics is 3K monthly website visits, up 42.9% over the last three months. Ray Therapeutics's team grew 33.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
4BIO Capital
California Institute for Regenerative Medicine
Series A10 investors entered at this stage
Novo Ventures
Norwest Venture Partners
Deerfield
MRL Ventures
Platanus Ventures
Janus Henderson Investors
Marshall Wace
Franklin Templeton
Invus
Adage Capital
Other known investors1 additional known investor
Wayne State University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ray Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ray Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.